294 related articles for article (PubMed ID: 26830211)
21. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.
Gopal AK; Rajendran JG; Petersdorf SH; Maloney DG; Eary JF; Wood BL; Gooley TA; Bush SA; Durack LD; Martin PJ; Matthews DC; Appelbaum FR; Bernstein ID; Press OW
Blood; 2002 May; 99(9):3158-62. PubMed ID: 11964278
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
24. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.
Pott C; Schrader C; Gesk S; Harder L; Tiemann M; Raff T; Brüggemann M; Ritgen M; Gahn B; Unterhalt M; Dreyling M; Hiddemann W; Siebert R; Dreger P; Kneba M
Blood; 2006 Mar; 107(6):2271-8. PubMed ID: 16332971
[TBL] [Abstract][Full Text] [Related]
25. [Current therapeutic strategies for mantle cell lymphoma].
Dreyling M; Schnaiter A; Schmidt C; Hoster E
Internist (Berl); 2016 Mar; 57(3):230-7. PubMed ID: 26886710
[TBL] [Abstract][Full Text] [Related]
26. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
27. Mantle Cell Lymphoma: Which Patients Should We Transplant?
Gerson JN; Barta SK
Curr Hematol Malig Rep; 2019 Aug; 14(4):239-246. PubMed ID: 31218478
[TBL] [Abstract][Full Text] [Related]
28. Diffuse aggressive lymphoma.
Fisher RI; Miller TP; O'Connor OA
Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
[TBL] [Abstract][Full Text] [Related]
29. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database.
Salek D; Vesela P; Boudova L; Janikova A; Klener P; Vokurka S; Jankovska M; Pytlik R; Belada D; Pirnos J; Moulis M; Kodet R; Michal M; Janousova E; Muzik J; Mayer J; Trněný M
Leuk Lymphoma; 2014 Apr; 55(4):802-10. PubMed ID: 23772666
[TBL] [Abstract][Full Text] [Related]
30. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
Dreger P; Martin S; Kuse R; Sonnen R; Glass B; Kröger N; Parwaresch R; Kneba M; Schmitz N; Haas R
Hematol J; 2000; 1(2):87-94. PubMed ID: 11920175
[TBL] [Abstract][Full Text] [Related]
31. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
32. Management of mantle cell lymphoma in the elderly: current and potential strategies.
Vignon M; Venon MD; Hermine O; Delarue R
Drugs Aging; 2013 Dec; 30(12):979-86. PubMed ID: 24178346
[TBL] [Abstract][Full Text] [Related]
33. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.
Magni M; Di Nicola M; Devizzi L; Matteucci P; Lombardi F; Gandola L; Ravagnani F; Giardini R; Dastoli G; Tarella C; Pileri A; Bonadonna G; Gianni AM
Blood; 2000 Aug; 96(3):864-9. PubMed ID: 10910898
[TBL] [Abstract][Full Text] [Related]
34. Optimal management of mantle cell lymphoma in the primary setting.
Tang C; Kuruvilla J
Expert Rev Hematol; 2019 Sep; 12(9):715-721. PubMed ID: 31268728
[No Abstract] [Full Text] [Related]
35. Evolving treatment strategies in mantle cell lymphoma.
Edwin NC; Kahl B
Best Pract Res Clin Haematol; 2018 Sep; 31(3):270-278. PubMed ID: 30213396
[TBL] [Abstract][Full Text] [Related]
36. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma.
Vose JM; Bierman PJ; Weisenburger DD; Lynch JC; Bociek Y; Chan WC; Greiner TC; Armitage JO
Biol Blood Marrow Transplant; 2000; 6(6):640-5. PubMed ID: 11128815
[TBL] [Abstract][Full Text] [Related]
37. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
[TBL] [Abstract][Full Text] [Related]
38. Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan.
Miura K; Takasaki H; Tsujimura H; Kanno M; Maeda Y; Tomita N; Takai K; Masaki Y; Takizawa J; Mori H; Terasaki Y; Yoshida T; Takeuchi J; Motomura S
Int J Hematol; 2011 May; 93(5):684-686. PubMed ID: 21479980
[No Abstract] [Full Text] [Related]
39. Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies.
Cohen JB; Zain JM; Kahl BS
Am Soc Clin Oncol Educ Book; 2017; 37():512-525. PubMed ID: 28561694
[TBL] [Abstract][Full Text] [Related]
40. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
